Výsledky vyhledávání - Omid Hamid

Upřesnit hledání
  1. 1
    Intratumoral Immunotherapy—Update 2019

    Intratumoral Immunotherapy—Update 2019 Autor Omid Hamid, Rubina Ismail, Igor Puzanov

    Vydáno 2019
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future

    Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future Autor Allison Betof Warner, Pippa Corrie, Omid Hamid

    Vydáno 2022
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer

    Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer Autor Omid Hamid, Brianna Hoffner, Eduard Gasal, Jenny J. Hong, Richard D. Carvajal

    Vydáno 2017
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Prevalence and Associated Factors of Low Birth Weight in Central Sudan: A Cross-sectional Study

    Prevalence and Associated Factors of Low Birth Weight in Central Sudan: A Cross-sectional Study Autor Nagat B. Elhag, Hager M. Alabass, Omid Hamid, Khalid Albasheer, Ishag Adam

    Vydáno 2025
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

    Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma Autor Omid Hamid, C. Lance Cowey, M Offner, Mark B. Faries, Richard D. Carvajal

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

    Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab Autor Vafa Shahabi, Gena S. Whitney, Omid Hamid, Henrik Schmidt, Scott D. Chasalow, Suresh Alaparthy, Jeffrey R. Jackson

    Vydáno 2012
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study

    Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study Autor Dmitriy Zamarin, Omid Hamid, Asha Nayak-Kapoor, Solmaz Sahebjam, Mario Sznol, Agron Collaku, Floyd E. Fox, Margaret Marshall, David S. Hong

    Vydáno 2020
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

    Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors Autor Robert H. Vonderheide, Jennifer M. Burg, Rosemarie Mick, Jennifer A. Trosko, Dongguang Li, M. Naveed Shaik, Anthony W. Tolcher, Omid Hamid

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers

    Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers Autor Christopher J.D. Wallis, Mohit Butaney, Raj Satkunasivam, Stephen J. Freedland, Sandip Pravin Patel, Omid Hamid, Sumanta K. Pal, Zachary Klaassen

    Vydáno 2019
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  10. 10
    A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

    A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma Autor Shailender Bhatia, Anna C. Pavlick, Peter D. Boasberg, John A. Thompson, George Mulligan, Michael D. Pickard, Hélène M. Faessel, Bruce J. Dezube, Omid Hamid

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma Autor Dirk Schadendorf, F. Stephen Hodi, Caroline Robert, Jeffrey S. Weber, Kim Margolin, Omid Hamid, Debra A. Patt, Tai‐Tsang Chen, David M. Berman, Jedd D. Wolchok

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

    Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies Autor Célèste Lebbé, Jeffrey S. Weber, Michele Maio, Bart Neyns, Kaan Harmankaya, Omid Hamid, Steven O’Day, Cyril Konto, L. Cykowski, M. Brent McHenry, Jedd D. Wolchok

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

    Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria Autor Jedd D. Wolchok, Axel Hoos, Steven O’Day, Jeffrey S. Weber, Omid Hamid, Célèste Lebbé, Michele Maio, Michael Binder, Oliver Bohnsack, Geoffrey Nichol, Rachel Humphrey, F. Stephen Hodi

    Vydáno 2009
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

    A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma Autor Omid Hamid, Henrik Schmidt, Aviram Nissan, Laura Ridolfi, Steinar Aamdal, Johan Hansson, Michele Guida, David M. Hyams, Henry Gómez, Lars Bastholt, Scott D. Chasalow, David M. Berman

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    A Phase I Multi-Arm Dose-Expansion Study of the Anti-Programmed Cell Death-Ligand-1 (Pd-L1) Antibody Medi4736: Preliminary Data

    A Phase I Multi-Arm Dose-Expansion Study of the Anti-Programmed Cell Death-Ligand-1 (Pd-L1) Antibody Medi4736: Preliminary Data Autor Neil H. Segal, Omid Hamid, W. Hwu, Christophe Massard, Marcus O. Butler, Scott Antonia, Andy Blake-Haskins, Paul B. Robbins, X. Li, Jim Vasselli, Samir N. Khleif

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

    Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma Autor Igor Puzanov, Mohammed Milhem, David R. Minor, Omid Hamid, Li Ai, Lisa Chen, Michael Chastain, Kevin Gorski, Abraham Anderson, Jeffrey Chou, Howard L. Kaufman, Robert H.I. Andtbacka

    Vydáno 2016
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

    A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patient... Autor Jeffrey S. Weber, John A. Thompson, Omid Hamid, David R. Minor, Asim Amin, Ilan G. Ron, Ruggero Ridolfi, Hazem Assi, Anthony Maraveyas, David M. Berman, Jonathan Siegel, Steven O’Day

    Vydáno 2009
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

    Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Autor Susan F. Slovin, Celestia S. Higano, Omid Hamid, Sheela Tejwani, Andrea Harzstark, Joshi J. Alumkal, Howard I. Scher, Kevin M. Chin, Paul Gagnier, M. Brent McHenry, Tomasz M. Beer

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    An immune-active tumor microenvironment favors clinical response to ipilimumab

    An immune-active tumor microenvironment favors clinical response to ipilimumab Autor Rui‐Ru Ji, Scott D. Chasalow, Lisu Wang, Omid Hamid, Henrik Schmidt, John Cogswell, Suresh Alaparthy, David M. Berman, Maria Jure–Kunkel, Nathan O. Siemers, Jeffrey R. Jackson, Vafa Shahabi

    Vydáno 2011
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

    Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma Autor Geoffrey T. Gibney, Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Mitchell, Thomas F. Gajewski, Bartosz Chmielowski, Brent A. Hanks, Yufan Zhao, Robert Newton, Janet Maleski, Lance Leopold, Jeffrey S. Weber

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: